NASDAQ: LFVN · Life Sciences · 5 alerts · CIK 849146
Share price
$4.77Close, Nov 16
Market cap
$59.8M
Shares outstanding
12.53MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Lifevantage Corp filings on SEC EDGAR ↗
Lifevantage Director Michael A. Beindorff Sells $48.9K of Stock
Michael A. Beindorff, Director, sold 10,000 shares of Lifevantage Corp at $4.89 a share, worth $48.9K in total on Nov 12, 2026. Shares held after the trade: 31,625 (-24.0%).
LifeVantage Corporation held its fiscal year 2027 annual meeting of stockholders on November 5, 2026. Shareholders elected six directors to the board, approved executive compensation on an advisory basis, and ratified Deloitte & Touche, LLP as the independent accounting firm for the fiscal year ending June 30, 2027.
LifeVantage Corp reported financial results for the first quarter of fiscal 2027, with revenue declining 22% to $37.1 million due to lower active accounts and GLP-1 system sales. The company reported a net loss of $0.02 per diluted share and is implementing a new strategy to transform into a brand-driven, consumer-focused company with a more efficient operating model.
Term
Q1 2027
“Despite a challenging quarter, LifeVantage has significant untapped potential, and we now have a clear strategy designed to capture it. Our focus is on transforming LifeVantage into a more brand-driven, consumer-focused company, supported by a modern digital platform and an expanding community of consumers and brand advocates.”
Terrence Moorehead, President and Chief Executive Officer
LifeVantage reported a net loss of $0.2 million for the quarter ended September 30, 2026, compared to a net income of $2.2 million in the prior year period. Revenue decreased significantly to $37.1 million from $47.6 million, driven by lower sales and the closure of markets in Hong Kong and Singapore.